An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Clinical trial NCT02531516 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02531516
- Sponsor
- Aragon Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-19
- Primary completion
- 2026-06-30
- Enrollment
- 1503
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.